# Experimental Therapeutics

> **NIH NIH P30** · UNIVERSITY OF IOWA · 2022 · $33,883

## Abstract

PROJECT SUMMARY/ABSTRACT 
Research in the Experimental Therapeutics (ET) program focuses on identification, development and testing of 
new cancer therapeutics. This is accomplished through three overlapping specific aims centered on 1) 
identifying potential targets and discovering therapeutics leads, 2) conducting preclinical evaluation of 
promising new therapeutic approaches, and 3) evaluating innovative and promising agents, combinations, and 
approaches to monitoring response in clinical trials. ET investigators are highly collaborative. Key scientific 
achievements of ET investigators over the prior funding period include identification of novel therapeutic 
targets in endometrial cancer and myeloma, nanoparticle based drug development, cancer immunotherapy 
based on toll-like receptor (TLR9) agonists, use of pharmacologic ascorbate to enhance the efficacy and 
reduce the toxicity of both chemotherapy and radiation therapy (in collaboration with the FRMI Program), and 
expansion of investigator-initiated and Phase I capabilities including trials of intralesional therapy. There are 28 
full and 16 associate members of ET including laboratory-based, translational and clinical investigators 
spanning 13 departments across five colleges. Annual total peer-reviewed cancer direct costs in the most 
recent budget year was $2.7 million ($1.9 million from the NCI). Additional funding included $3.8 million for 
non-peer-reviewed research projects. ET members are highly collaborative having authored or co-authored 
291 cancer-related peer-reviewed publications in the past five years, with 24% (n= 69) intraprogrammatic, 43% 
(n= 124) interprogrammatic, and 42% (n= 123) interinstitutional publications. Twenty-nine manuscripts 
appeared in high impact journals (Impact Factor ≥10).

## Key facts

- **NIH application ID:** 10395520
- **Project number:** 5P30CA086862-22
- **Recipient organization:** UNIVERSITY OF IOWA
- **Principal Investigator:** Aliasger K Salem
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $33,883
- **Award type:** 5
- **Project period:** 2000-07-14 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10395520

## Citation

> US National Institutes of Health, RePORTER application 10395520, Experimental Therapeutics (5P30CA086862-22). Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/grant/nih/10395520. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*